EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)

Carmine De Angelis iD, Martina Pagliuca iD, Emanuela Magnolfi, Mauro Mansutti, Zelmira Ballatore, Michelino De Laurentiis, Roberto Bordonaro, Vita Leonardi, Dario Bruzzese iD, Roberta Caputo iD, Anna Maria Mosconi, Saverio Cinieri und 6 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf200 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Carmine De Angelis und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy. Hauptthemen laut MEDLINE: Lapatinib, Breast Neoplasms, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Oncotech, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab combined with chemotherapy is a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer in later lines. Lapatinib and trastuzumab have also demonstrated efficacy. This study assessed the efficacy, toxicity, and quality of life (QoL) of trastuzumab plus lapatinib (with endocrine therapy for hormone receptor-positive cases) versus trastuzumab with physician-selected chemotherapy in patients previously treated with at least 2 anti-HER2 regimens.

Methods

In this open-label, multicenter phase II trial, 59 patients were randomized 1:1 to receive either trastuzumab and lapatinib (arm A) or trastuzumab with chemotherapy (arm B). The primary endpoint was clinical benefit rate (CBR), defined as confirmed complete response, partial response, or stable disease for ≥24 weeks. Secondary endpoints included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), QoL, and safety.

Results

With a median follow-up of 57.5 months, the CBR was 20.7% in arm A and 26.7% in arm B (P = .76). The ORR was 13.8% versus 20.0% (P = .73), and median PFS was 3.6 months in arm A versus 6.1 months in arm B (HR 0.63; P = .08). Median OS was 29.9 versus 31.1 months (HR 1.07; P = .82). Adverse events occurred in 86.2% (arm A) and 66.7% (arm B) of patients, with grade 3–4 events in 24.1% and 13.3%, respectively. QoL favored arm A (P = .03). Due to early study closure and limited sample size, all results should be considered exploratory and not powered to assess definitive treatment effects.

Conclusions

While efficacy differences were not significant, trastuzumab with lapatinib showed better QoL despite higher adverse event rates, suggesting it may be a viable chemotherapy-free option for pretreated HER2-positive advanced breast cancer. EudraCT trial registration number 2013-005044-29

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LapatinibBreast NeoplasmsTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesHumansFemaleMiddle AgedAdultAgedQuality of Life

Stichwörter der Autor:innen

HER2chemo-free treatmentlapatinibmetastatic breast cancer

Substanzen

LapatinibTrastuzumabErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy.
  • Molecular Predictors and New Targets in Oncology, Inserm U981, Université Paris-Saclay, Gustave Roussy, 94800 Villejuif, France.
  • Medical Oncology, P.O. SS Trinità, ASL Frosinone, Sora, Italy.
  • Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
  • Oncology, AST PU Presidio Santa Croce, Fano, Italy.
  • Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Napoli, Italy.

ORCID-Profile: Carmine De Angelis, Martina Pagliuca, Dario Bruzzese, Roberta Caputo, Fabio Puglisi, Grazia Arpino

Förderung

  • Oncotech
  • Novartis

Zitieren

APA

De Angelis, C., Pagliuca, M., Magnolfi, E., Mansutti, M., Ballatore, Z., De Laurentiis, M., Bordonaro, R., Leonardi, V., Bruzzese, D., Caputo, R., Mosconi, A. M., Cinieri, S., Fabi, A., Del Mastro, L., Puglisi, F., De Placido, S., Giuliano, M., & Arpino, G. (2025). Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER). The Oncologist. https://doi.org/10.1093/oncolo/oyaf200

Vancouver

De Angelis C, Pagliuca M, Magnolfi E, Mansutti M, Ballatore Z, De Laurentiis M, et al. Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER). The Oncologist. 2025. doi:10.1093/oncolo/oyaf200

BibTeX
@article{DeAngelis2025,
  author = {De Angelis, Carmine and Pagliuca, Martina and Magnolfi, Emanuela and Mansutti, Mauro and Ballatore, Zelmira and De Laurentiis, Michelino and Bordonaro, Roberto and Leonardi, Vita and Bruzzese, Dario and Caputo, Roberta and Mosconi, Anna Maria and Cinieri, Saverio and Fabi, Alessandra and Del Mastro, Lucia and Puglisi, Fabio and De Placido, Sabino and Giuliano, Mario and Arpino, Grazia},
  title = {Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf200}
}
Kostenlos starten →